专利检索 ipc:"C07C233/80" 第 1 页

1.

发明授权
Farnesoid X receptor agonists and uses thereof 有权

公开(公告)号：US11214538B2

公开(公告)日：2022-01-04

申请号：US16872985

申请日：2020-05-12

申请人： Metacrine, Inc.

发明人： Nicholas D. Smith , Steven P. Govek , Johnny Y. Nagasawa

IPC分类号： C07C233/80 , C07C233/63 , A61K31/167 , A61K31/216 , C07D333/32 , C07D239/34 , C07D241/18 , C07D263/32 , C07D205/04 , C07D207/27 , C07D275/03 , C07D277/34 , C07D213/65 , A61K45/06 , C07D207/12 , C07D213/75 , C07D207/08 , C07D213/68 , C07D211/42 , C07D211/46 , C07D213/40 , C07D213/64 , C07D213/80 , C07C271/20 , C07C237/22 , C07C237/42 , C07C233/59 , C07C233/62 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/421 , A61K31/425 , A61K31/426 , A61K31/4418 , A61K31/445 , A61K31/4965 , A61K31/505 , C07D207/24 , C07D211/94

摘要： Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

2.

发明申请
FARNESOID X RECEPTOR AGONISTS AND USES THEREOF 有权

公开(公告)号：US20210032195A1

公开(公告)日：2021-02-04

申请号：US16872985

申请日：2020-05-12

申请人： Metacrine, Inc.

发明人： Nicholas D. SMITH , Steven P. GOVEK , Johnny Y. NAGASAWA

IPC分类号： C07C233/80 , C07D333/32 , C07D239/34 , C07D241/18 , C07D263/32 , C07D205/04 , C07D207/27 , C07D275/03 , C07D277/34 , C07D213/65 , A61K45/06 , C07D207/12 , C07D213/75 , C07D207/08 , C07D213/68 , C07D211/42 , C07D211/46 , C07D213/40 , C07D213/64 , C07D213/80 , C07C271/20 , C07C233/63 , C07C237/22 , C07C237/42 , C07C233/59 , C07C233/62 , A61K31/167 , A61K31/216 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/421 , A61K31/425 , A61K31/426 , A61K31/4418 , A61K31/445 , A61K31/4965 , A61K31/505 , C07D207/24 , C07D211/94

摘要： Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

3.

发明授权
Farnesoid X receptor agonists and uses thereof 有权

公开(公告)号：US10703712B2

公开(公告)日：2020-07-07

申请号：US15758707

申请日：2016-09-16

申请人： Metacrine, Inc.

发明人： Nicholas D. Smith , Steven P. Govek , Johnny Y. Nagasawa

IPC分类号： C07C233/80 , A61K31/44 , C07D333/32 , C07D239/34 , C07D241/18 , C07D263/32 , C07D205/04 , C07D207/27 , C07D275/03 , C07D277/34 , C07D213/65 , A61K45/06 , C07D207/12 , C07D213/75 , C07D207/08 , C07D213/68 , C07D211/42 , C07D211/46 , C07D213/40 , C07D213/64 , C07D213/80 , C07C271/20 , C07C233/63 , C07C237/22 , C07C237/42 , C07C233/59 , C07C233/62 , A61K31/167 , A61K31/216 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/421 , A61K31/425 , A61K31/426 , A61K31/4418 , A61K31/445 , A61K31/4965 , A61K31/505 , C07D207/24 , C07D211/94

摘要： Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

4.

发明申请
ANTHRACENE DERIVATIVES CONTAINING BENZIMIDAZOLE OR BORATE AND ORGANOELECTROLUMINESCENT DEVICE INCLUDING THE SAME 审中-公开

公开(公告)号：US20200028088A1

公开(公告)日：2020-01-23

申请号：US16194974

申请日：2018-11-19

申请人： YUAN ZE UNIVERSITY , NICHEM FINE TECHNOLOGY CO., LTD. , TETRAHEDRON TECHNOLOGY CORPORATION , WAN HSIANG PRECISION MACHINERY CO., LTD.

发明人： Tien-Lung CHIU , Jiun-Haw LEE , Man-Kit LEUNG , Chi-Feng LIN , Liang-Ju HOU , Bo-An FAN , Chiou-Ling CHANG

IPC分类号： H01L51/00 , C07D235/20 , C09K11/06 , C07C233/80 , C07D235/18

摘要： An organic light-emitting diode comprises a first electrode layer, a second electrode layer, and an organic luminescent unit disposed between the first electrode layer and the second electrode layer. The organic luminescent unit has an organic electroluminescent material containing anthracene group as shown in General Formula (1): wherein A is selected from the group consisting of General Formula (2), General Formula (3) and General Formula (4): wherein B is selected from the group consisting of General Formula (5), General Formula (6) and General Formula (7): B is General Formula (5) when A is selected from the group consisting of General Formula (2) and General Formula (3); B is selected from the group consisting of General Formula (6) and General Formula (7) when A is General Formula (4); and wherein R1 to R43 are independently selected from the group consisting of hydrogen atom, fluorine atom, cyano group, alkyl group, cycloalkyl group, alkoxy group, haloalkyl group, thioalkyl group, silyl group and alkenyl group.

5.

发明授权
Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration 有权

公开(公告)号：US10118890B2

公开(公告)日：2018-11-06

申请号：US15516610

申请日：2015-10-09

申请人： Ming-Yu Ngai , Katarzyna N. Hojczyk

发明人： Ming-Yu Ngai , Katarzyna N. Hojczyk

IPC分类号： C07C233/25 , C07C259/06 , C07C259/10 , C07D239/91 , C07C231/12 , C07C255/60 , C07C253/30 , C07C233/33 , C07C233/80 , C07C233/54 , C07C233/81 , C07D215/40 , C07D209/08 , C07D213/75 , C07D401/04 , C07D473/40 , C07D213/76

摘要： The present invention provides a process of producing a trifluoromethoxylated aryl or trifluoromethoxylated heteroaryl having the structure: wherein A is an aryl or heteroaryl, each with or without subsutitution; and R1 is —H, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(alkylaryl), -(alkylheteroaryl), —NH-(alkyl), —N(alkyl)2, —NH-(alkenyl), —NH-(alkynyl)—NH-(aryl), —NH-(heteroaryl), —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), or —S-(heteroaryl), comprising: (a) reacting a compound having the structure: with a trifluoromethylating agent in the presence of a base in a first suitable solvent under conditions to produce a compound having the structure: and (b) maintaining the compound produced in step (a) in a second suitable solvent under conditions sufficient to produce the trifluoromethoxylated aryl or trifluormethoxylated heteroaryl having the structure:

6.

发明授权
Ceramide derivatives having agonistic effects on epidermal cannabinoid receptors, and pharmaceutical or cosmetic composition containing same 有权

公开(公告)号：US09796665B2

公开(公告)日：2017-10-24

申请号：US14916079

申请日：2014-09-01

申请人： NEOPHARM CO., LTD.

发明人： Se Kyoo Jeong , Bong-Woo Kim , Jeong Eun Jeon , Bu-Mahn Park

IPC分类号： C07C235/76 , C07C233/80

CPC分类号： C07C235/76 , C07C233/80

摘要： The present invention relates to a novel pseudoceramide derivative, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutical or cosmetic composition containing the same as an active ingredient. The novel pseudoceramide derivative of the present invention is expected to be very useful for treating or preventing skin diseases by activating cannabinoid receptors. In addition, the novel pseudoceramide derivative, the pharmaceutically acceptable salt thereof or the solvate thereof, of the present invention, has a simple synthesis process compared with a known cannabinoid receptor antagonist so as to reduce processing time and curtail material costs, and thus is economical, and has advantages such as easy emulsification during the formulation of cosmetic products or medical supplies.

7.

发明授权
Monomer for hardmask composition, hardmask composition including the monomer, and method of forming patterns using the hardmask composition 有权

公开(公告)号：US09683114B2

公开(公告)日：2017-06-20

申请号：US14609824

申请日：2015-01-30

申请人： SAMSUNG SDI CO., LTD.

发明人： Hea-Jung Kim , Sung-Hwan Kim , Youn-Hee Nam , Yun-Jun Kim , Joon-Young Moon , Hyun-Ji Song , Yong-Woon Yoon , Chung-Heon Lee

IPC分类号： G03F7/004 , G03F7/09 , C07C251/24 , C07C233/80 , C09D7/12 , G03F7/075

CPC分类号： C09D7/63 , C07C233/80 , C07C251/24 , C07C2603/18 , C07C2603/24 , C07C2603/50 , C09D5/006 , G03F7/0752 , G03F7/094

摘要： A monomer for a hardmask composition, a hardmask composition, and a method of forming patterns, the monomer being represented by the following Chemical Formula 1:

8.

发明授权
Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof 有权

公开(公告)号：US09603950B1

公开(公告)日：2017-03-28

申请号：US14922159

申请日：2015-10-25

申请人： Ming-Hsin Li , Chyng-Yann Shiue , Han-Chih Chang , Han-Hsiang Chu

发明人： Ming-Hsin Li , Chyng-Yann Shiue , Han-Chih Chang , Han-Hsiang Chu

IPC分类号： C07C237/40 , C07C231/12 , A61K51/04 , C07C233/80

CPC分类号： A61K51/04 , C07B59/001 , C07B2200/05 , C07C233/80 , C07C237/40

摘要： A method of synthesizing a compound of imaging agent with HDAC (histone deacetylase) inhibitor consists of two parts, the first part of the method is to provide the inhibitor of HDAC with a compound of imaging agent that includes HDAC inhibitor BNL-26 (C22H23N3O) and its analogs to be labeled with radionuclide F-18, producing a series of new nuclear medicine tracers: BNL-26-CH2CH218F, BNL-26a-CH2CH218FF, BNL-26b-CH2CH218F, BNL-26c-CH2CH218F and BNL-26d-CH2CH218F. These nuclear medicine with imaging agents can be used as a tracer in vivo binding to over-expression HDAC and produce a HDAC nuclear medicine imaging effect to serve for clinical diagnosis. The second part of the method is to provide a slightly adjusted a structural framework of BNL-26 and use pyridine to substitute the benzene ring of the BNL-26 structure, and then synthesize with other substituent to produce a series of additional 30 more HDAC inhibitors, named from Iner-1 to Iner-30 compounds.

9.

发明授权
Processes for making ponatinib and intermediates thereof 有权
标题翻译：制备潘他滨及其中间体的方法

公开(公告)号：US09493473B2

公开(公告)日：2016-11-15

申请号：US14984446

申请日：2015-12-30

申请人： Apicore US LLC

发明人： Ravishanker Kovi , Jayaraman Kannapan , Sanjay F. Thakor , Rajesh A Patel

IPC分类号： C07D487/04 , C07D209/48 , C07C233/80 , C07C233/75 , C07C233/76 , C07D233/80 , C07D233/76

CPC分类号： C07D487/04 , C07C233/75 , C07C233/76 , C07C233/80 , C07D209/48

摘要： Novel synthetic approaches to make 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof are provided.

摘要翻译： 制备3-（咪唑并[1,2-b]哒嗪-3-基乙炔基）-4-甲基-N- [4 - [（4-甲基哌嗪-1-基）甲基] -3-（三氟甲基）苯基]苯甲酰胺，其中间体及其药学上可接受的盐。